Page 278 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHAPTER 17 Cytotoxic T Lymphocytes and Natural Killer Cells 259

11. Attanasio J, Wherry EJ. Costimulatory and coinhibitory receptor pathways 22. Das J, Khakoo SI. NK cells: tuned by peptide? Immunol Rev
in infectious disease. Immunity 2016;44:1052–68. 2015;267:214–27.
12. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: 23. Scully E, Alter G. NK Cells in HIV Disease. Curr HIV/AIDS Rep
toward combination strategies with curative potential. Cell 2016;13:85–94.
2015;161(2):205–14. 24. Cerwenka A, Lanier LL. Natural killer cell memory in infection,
13. Reguzova AY, Karpenko LI, Mechetina LV, et al. Peptide-MHC inflammation and cancer. Nat Rev Immunol 2016;16:112–23.
multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS 25. Fang M, Orr MT, Spee P, et al. CD94 is essential for NK cell-mediated
vaccine development. Expert Rev Vaccines 2015;14:69–84. resistance to a lethal viral disease. Immunity 2011;34:579–89.
14. Seillet C, Belz GT, Huntington ND. Development, homeostasis, and 26. Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the
heterogeneity of NK Cells and ILC1. Curr Top Microbiol Immunol NKG2D activating receptor. Annu Rev Immunol 2013;31:413–41.
2016;395:37–61. 27. Kruse PH, Matta J, Ugolini S, et al. Natural cytotoxicity receptors and
15. Huntington ND. The unconventional expression of IL-15 and its role in their ligands. Immunol Cell Biol 2014;92:221–9.
NK cell homeostasis. Immunol Cell Biol 2014;92:210–13. 28. Kadri N, Thanh TL, Hoglund P. Selection, tuning, and adaptation in
16. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural mouse NK cell education. Immunol Rev 2015;267:167–77.
killer cell development. Trends Immunol 2013;34:573–82. 29. Moretta L, Montaldo E, Vacca P, et al. Human natural killer cells: origin,
17. Brady J, Carotta S, Thong RP, et al. The interactions of multiple cytokines receptors, function, and clinical applications. Int Arch Allergy Immunol
control NK cell maturation. J Immunol 2010;185:6679–88. 2014;164:253–64.
18. Guillerey C, Huntington ND, Smyth MJ. Targeted natural killer cells in 30. Chijioke O, Munz C. Dendritic cell derived cytokines in human natural
cancer immunotherapy. Nat Immunol 2016;17:1025–36. killer cell differentiation and activation. Front Immunol 2013;4:365.
19. Croce M, Rigo V, Ferrini S. IL-21: a pleiotropic cytokine with potential 31. Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive
applications in oncology. J Immunol Res 2015;2015:696578. immunity to cancer. Annu Rev Immunol 2011;29:235–71.
20. Pegram HJ, Andrews DM, Smyth MJ, et al. Activating and inhibitory 32. Alzhanova D, Fruh K. Modulation of the host immune response by
receptors of natural killer cells. Immunol Cell Biol 2011;89:216–24. cowpox virus. Microbes Infect 2010;12:900–9.
21. Guethlein LA, Norman PJ, Hilton HH, et al. Co-evolution of MHC class I 33. Christiaansen A, Varga SM, Spencer JV. Viral manipulation of the host
and variable NK cell receptors in placental mammals. Immunol Rev immune response. Curr Opin Immunol 2015;36:54–60.
2015;267:259–82.